iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
8.97
+0.16 (1.82%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.

The company’s lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or FcγR to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials.

Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

iTeos Therapeutics, Inc.
iTeos Therapeutics logo
Country United States
Founded 2011
IPO Date Jul 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 157
CEO Michel Detheux

Contact Details

Address:
321 Arsenal Street, Suite 301
Watertown, Massachusetts 02472
United States
Phone 339 217 0161
Website iteostherapeutics.com

Stock Details

Ticker Symbol ITOS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001808865
CUSIP Number 46565G104
ISIN Number US46565G1040
SIC Code 2836

Key Executives

Name Position
Dr. Michel Detheux Ph.D. President, Chief Executive Officer and Director
Matthew Gall Chief Financial Officer
Matthew A. Call M.B.A. Chief Operating Officer
Dr. Yvonne McGrath Ph.D. Chief Scientific Officer
Adi Osovsky Executive Vice President of Legal
Philippe Brantegem Executive Vice President of Human Resources
Dr. David Feltquate M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 8-K Current Report
Oct 21, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 15, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 15, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 30, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 16, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Jun 13, 2024 8-K Current Report
May 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
May 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership